 Stanley Muller on Aug 17th, 2018 // No Comments
Royal Bank of Canada upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a sector perform rating to an outperform rating in a research report released on Monday, Marketbeat Ratings reports. Royal Bank of Canada currently has $26.00 price target on the stock.
Several other research analysts have also commented on the company. BMO Capital Markets raised their price objective on Endo International from $9.00 to $16.00 and gave the company a market perform rating in a research report on Friday, August 10th. They noted that the move was a valuation call. Leerink Swann raised their price objective on Endo International from $12.00 to $18.00 and gave the company a market perform rating in a research report on Thursday, August 9th. Stifel Nicolaus raised their price objective on Endo International from $10.00 to $17.00 and gave the company a hold rating in a research report on Thursday, August 9th. Citigroup raised their price objective on Endo International from $11.00 to $19.00 and gave the company a buy rating in a research report on Thursday, August 9th. Finally, ValuEngine raised Endo International from a hold rating to a buy rating in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of $13.39. Get Endo International alerts:
NASDAQ:ENDP opened at $15.95 on Monday. The company has a debt-to-equity ratio of -132.64, a quick ratio of 0.91 and a current ratio of 1.07. Endo International has a 12 month low of $5.27 and a 12 month high of $17.34. The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of 4.16, a P/E/G ratio of 3.01 and a beta of 0.49.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The company had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same period last year, the company posted $0.93 earnings per share. The firm's revenue was down 18.4% compared to the same quarter last year. equities research analysts anticipate that Endo International will post 2.6 EPS for the current fiscal year.
In other news, Director Roger H. Kimmel sold 26,074 shares of Endo International stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . 0.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA increased its holdings in Endo International by 518.7% in the first quarter. BNP Paribas Arbitrage SA now owns 3,293,567 shares of the company's stock valued at $19,564,000 after buying an additional 2,761,216 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company's stock valued at $23,074,000 after buying an additional 284,599 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Endo International by 1.0% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company's stock valued at $10,375,000 after buying an additional 10,600 shares during the last quarter. Schroder Investment Management Group increased its holdings in Endo International by 78.1% in the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company's stock valued at $7,349,000 after buying an additional 327,775 shares during the last quarter. Finally, River & Mercantile Asset Management LLP increased its holdings in Endo International by 18.6% in the second quarter. River & Mercantile Asset Management LLP now owns 554,835 shares of the company's stock valued at $5,229,000 after buying an additional 87,102 shares during the last quarter. 95.89% of the stock is currently owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚